Matthias Leschke1, Matthias Waliszewski2, Maxime Pons3, Stanislas Champin4, Lyassine Nait Saidi5, Tay Mok Heang6, Oteh Maskon7, Wan Azman Bin Wan Ahmad8, Denny Herberger2, Marc-Eric Moulichon9, Jérôme Rischner10, Christophe Robin11, Florence Leclercq12, Jean-Pascal Peyre13, Benjamin Faurie14, André Schneider15. 1. Klinik für Kardiologie, Angiologie und Pneumologie, Klinikum Esslingen, Esslingen, Germany. m.leschke@klinikum-esslingen.de. 2. Medical Scientific Affairs B. Braun Vascular Systems, Berlin, Germany. 3. Cardiologie Interventionelle, Clinique Du Millénaire, Grenoble, France. 4. Cardiologie et Rythmologie interventionnelle, Centre Hospitalier De Valence, France. 5. Pôle Cardiologie vasculaire, Cardiologie, Centre Hospitalier Sainte Musse, France. 6. Cardiology, Pantai Hospital Ayer Keroh, Malacca, Malaysia. 7. Cardiology, Pusat Perubatan UKM, Kuala Lumpur, Malaysia. 8. Cardiology, Pusat Perubatan Universiti Malaya, Kuala Lumpur, Malaysia. 9. Cardiologie interventionnelle, électrophysiologie, Clinique Saint-Pierre Perpignan, France. 10. Cardiologie, Hôpital Albert Schweitzer, Colmar, France. 11. Cardio-Vasculaire, Clinique Convert, Bourg En Bresse, France. 12. Département Cardiologie et Maladies Vasculaire, Centre Hospitalier Universitaire Montpellier, France. 13. Cardiologie - Pathologie cardio vasculaire, Hôpital Privé Beauregard, Marseille, France. 14. Cardiologie, Groupe Hospitalier Mutualiste, Grenoble, France. 15. Klinik für Kardiologie, Angiologie und Pneumologie, Klinikum Esslingen, Esslingen, Germany.
Abstract
OBJECTIVES: This observational study assessed the 9-month clinical outcomes in an « all comers » population with a focus on patients with atrial fibrillation (AF) after thin strut bare metal stenting. BACKGROUND: Drug eluting stent (DES) implantation is the treatment of choice for coronary artery disease (CAD) leaving only marginal indications for the use of bare metal stents (BMS). However, selected treatment populations with DES contraindications such as patients who cannot sustain 6-12 months of dual antiplatelet therapy (DAPT) remain candidates for BMS implantations. METHODS: Thin strut bare metal stenting in a priori defined subgroups were investigated in a non-randomized, international, multicenter «all comers» observational study. Primary endpoint was the 9-month TLR rate whereas secondary endpoints included the 9-month MACE and procedural success rates. RESULTS: A total of 783 patients of whom 98 patients had AF underwent BMS implantation. Patient age was 70.4 ± 12.8 years. Cardiovascular risk factors in the overall population were male gender (78.2%, 612/783), diabetes (25.2%, 197/783), hypertension (64.1%, 502/783), cardiogenic shock (4.9%, 38/783) and end stage renal disease (4.9%, 38/783). In-hospital MACE was 4.1% (30/783) in the overall population. The 9-month TLR rate was 4.5% (29/645) in the non-AF group and 3.3% (3/90) in the AF group (P = 0.613). At 9 months, the MACE rate in the AF-group and non-AF group was not significantly different either (10.7%, 69/645 vs. 6.7%, 6/90; P = 0.237). Accumulated stroke rates were 0.3% (2/645) in the non-AF subgroup at baseline and 1.1% (1/90) in the AF subgroup (P = 0.264). CONCLUSION: Bare metal stenting in AF patients delivered acceptably low TLR and MACE rates while having the benefit of a significantly shorter DAPT duration in a DES dominated clinical practice.
OBJECTIVES: This observational study assessed the 9-month clinical outcomes in an « all comers » population with a focus on patients with atrial fibrillation (AF) after thin strut bare metal stenting. BACKGROUND: Drug eluting stent (DES) implantation is the treatment of choice for coronary artery disease (CAD) leaving only marginal indications for the use of bare metal stents (BMS). However, selected treatment populations with DES contraindications such as patients who cannot sustain 6-12 months of dual antiplatelet therapy (DAPT) remain candidates for BMS implantations. METHODS: Thin strut bare metal stenting in a priori defined subgroups were investigated in a non-randomized, international, multicenter «all comers» observational study. Primary endpoint was the 9-month TLR rate whereas secondary endpoints included the 9-month MACE and procedural success rates. RESULTS: A total of 783 patients of whom 98 patients had AF underwent BMS implantation. Patient age was 70.4 ± 12.8 years. Cardiovascular risk factors in the overall population were male gender (78.2%, 612/783), diabetes (25.2%, 197/783), hypertension (64.1%, 502/783), cardiogenic shock (4.9%, 38/783) and end stage renal disease (4.9%, 38/783). In-hospital MACE was 4.1% (30/783) in the overall population. The 9-month TLR rate was 4.5% (29/645) in the non-AF group and 3.3% (3/90) in the AF group (P = 0.613). At 9 months, the MACE rate in the AF-group and non-AF group was not significantly different either (10.7%, 69/645 vs. 6.7%, 6/90; P = 0.237). Accumulated stroke rates were 0.3% (2/645) in the non-AF subgroup at baseline and 1.1% (1/90) in the AF subgroup (P = 0.264). CONCLUSION: Bare metal stenting in AFpatients delivered acceptably low TLR and MACE rates while having the benefit of a significantly shorter DAPT duration in a DES dominated clinical practice.
Authors: Ahmad Syadi Mahmood Zuhdi; Florian Krackhardt; Matthias W Waliszewski; Muhammad Dzafir Ismail; Michael Boxberger; Wan Azman Wan Ahmad Journal: Cardiol Res Pract Date: 2018-03-01 Impact factor: 1.866
Authors: Florian Krackhardt; Matthias Waliszewski; Wan Azman Wan Ahmad; Viktor Kočka; Petr Toušek; Bronislav Janek; Milan Trenčan; Peter Krajči; Fernando Lozano; Koldobika Garcia-San Roman; Imanol Otaegui Irurueta; Bruno Garcia Del Blanco; Lucie Wachowiak; Victoria Vilalta Del Olmo; Eduard Fernandez Nofrerías; Myung Ho Jeong; Byung-Chun Jung; Kyu-Rock Han; Christophe Piot; Laurent Sebagh; Jérôme Rischner; Michel Pansieri; Matthias Leschke; Tae Hoon Ahn Journal: PLoS One Date: 2020-01-13 Impact factor: 3.240
Authors: Florian Krackhardt; Viktor Kočka; Matthias W Waliszewski; Andreas Utech; Meik Lustermann; Martin Hudec; Martin Studenčan; Markus Schwefer; Jiangtao Yu; Myung Ho Jeong; Taehoon Ahn; Wan Azman Wan Ahmad; Michael Boxberger; André Schneider; Matthias Leschke Journal: Open Heart Date: 2017-06-06